Sunday, October 2, 2022
HomeHealthcareThe state of AI in drug discovery

The state of AI in drug discovery


AI, machine learning, technology

In recent times there’s been an rising convergence between the worlds of well being tech and biopharma. Decentralized medical trials are an incredible instance of this pattern. However even earlier than the pandemic that led to the speedy scale of decentralized trials, biopharma corporations had been experimenting with varied applied sciences in R&D.

The usage of machine studying and different types of AI for drug growth is an thrilling pattern filled with potentialities, particularly because the expertise matures and firms adapt.

AI in drug growth is simply one of many panel discussions on the MedCity INVEST PhrmaTech digital convention, scheduled for Tuesday, July 26.

To view the total agenda, click on right here. Registration is free.

The convention will discover among the methods well being tech and biopharma intersect, from a dialog on digital medicines to digital medical trials.

The panel dialogue, the state of AI in drug discovery, will kick off the convention. Right here’s an outline:

Synthetic intelligence in healthcare is lastly rising from being overhyped to displaying some sensible purposes. If it succeeds within the realms of drug discovery, that might be a monumental achievement serving to each to hurry up and decrease the price for drug growth. Study from specialists about the place we’re in leveraging AI successfully for drug discovery.

Moderator: Frank Vinluan, Senior Biopharma Reporter, MedCity Information

Audio system:

  • Chris Gibson, Co-founder and CEO, Recursion
  • Richard Legislation, Chief Enterprise Officer, Exscientia
  • Sana Mujahid, Senior Scientist, Aria Prescribed drugs
  • Eric Steager, Enterprise Associate, Landing Ventures

There may also be a startup pitch contest. It can highlight corporations which are creating applied sciences to handle progressive approaches to medical trial design, affected person recruitment, distant affected person monitoring, and extra, all of which might rework medical trials.

Among the many judges for Pitch Good are:

  • Cris De Luca, Associate, Digital, Sanofi Ventures
  • Jessica Federer, Associate, Boston Millennia Companions
  • Joel Krikston, Managing Director Enterprise Investments & Head of Strategic Innovation Alliances, Merck International Well being Innovation Fund
  • Maxim Owen, Enterprise Associate, Wavemaker Three-Sixty Well being

 

Interested by sponsorship alternatives at this and different conferences by MedCity Information? Please contact MedCity Information Writer Ken Montgomery at kmontgomery@medcitynews.com.

 

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments